Immunology of human schistosomiasis: immunity, disease and co-infections

Lead Research Organisation: University of Cambridge
Department Name: Unlisted

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Publications

10 25 50

publication icon
Brown M (2006) Schistosoma mansoni, nematode infections, and progression to active tuberculosis among HIV-1-infected Ugandans. in The American journal of tropical medicine and hygiene

publication icon
Fitzsimmons CM (2004) Human IgE response to the Schistosoma haematobium 22.6 kDa antigen. in Parasite immunology

publication icon
McIntosh RS (2006) Characterization of immunoglobulin binding by schistosomes. in Parasite immunology

 
Description MUSTSchistUKEMA FP6 Follow on funding (1.5m euros across 7 participants)
Amount £175,714 (GBP)
Funding ID 517733 
Organisation Sixth Framework Programme (FP6) 
Sector Public
Country European Union (EU)
Start 09/2005 
End 08/2009
 
Description Dr A. Elliott and Dr. M. Brown (Uganda Institute of Virus Research and the MRC HIV Unit) 
Organisation MRC/UVRI Uganda Research Unit on AIDS
Country Uganda 
Sector Public 
PI Contribution NA
Collaborator Contribution Dr A. Elliott and Dr. M. Brown collaborated on studies on interactions between schistosomiasis, helminths and HIV infections.
Impact NA
 
Description Dr BJ. Vennervald (Institute for Health Research and Development, Charlottenlund, Denmark) 
Organisation University of Copenhagen
Department DBL - Centre for Health Research and Development
Country Denmark 
Sector Academic/University 
PI Contribution NA
Collaborator Contribution collaboration on clinical, ultrasonography, training aspects, plus additional logistic support for African partners; Dr CM. Reimert, collaboration in eosinophil studies
Impact NA
 
Description Dr CH. Hokke, Dr M. Weiner, Prof AM. Deelder (Leiden) 
Organisation Leiden University Medical Center
Country Netherlands 
Sector Multiple 
PI Contribution NA
Collaborator Contribution Leiden University Medical Center, Leiden, Netherlands: Dr CH. Hokke, Dr M. Weiner, Prof AM. Deelder, collaborative studies on the structure and glycosylation of S. mansoni antigens; Prof M. Yazdanbakhsh, collaboration on human antibody responses to S. haematobium Ags.
Impact NA
 
Description Dr J. Khalife (Insitute Pasteur) 
Organisation Pasteur Institute, Lille
Country France 
Sector Charity/Non Profit 
PI Contribution NA
Collaborator Contribution Institut Pasteur de Lille, Lille, France: Dr J. Khalife, collaboration on the identification of cross-reactive malaria/schistosome Ags.
Impact NA
 
Description Dr NB. Kabatereine, Dr F. Kazibwe (Ugandan Ministry of Health) 
Organisation Ministry of Health, Uganda
Country Uganda 
Sector Public 
PI Contribution NA
Collaborator Contribution contributed field workers/management, demonography, vector studies, community health coverage, parasitological screening, and to all aspects of community work in Uganda
Impact NA
 
Description Dr RA Sturrock (LSHTM) 
Organisation London School of Hygiene and Tropical Medicine (LSHTM)
Country United Kingdom 
Sector Academic/University 
PI Contribution NA
Collaborator Contribution London School of Hygiene and Tropical Medicine: Dr RA Sturrock, provided external quality control of parasitology teams in Kenya and Uganda.
Impact NA
 
Description Dr TA. Wynn (NIAID) 
Organisation National Institute of Allergy and Infectious Diseases (NIAID)
Country United States 
Sector Public 
PI Contribution NA
Collaborator Contribution National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, USA: Dr TA. Wynn, collaboration on the possible immunoregulatory role of the IL-13alpha-2 'decoy' receptor in human schistosomiasis.
Impact NA
 
Description Drs E. Mucheri, HC Kariuki (Kenyan Ministry of Health) 
Organisation Division of Vector Borne Diseases
Country Kenya 
Sector Public 
PI Contribution NA
Collaborator Contribution provided demonography, epidemiology, malocology, and entomology support in both Kenya and Uganda
Impact NA
 
Description Drs MA. Shaw, R. Quinnell (University of Leeds) 
Organisation University of Leeds
Country United Kingdom 
Sector Academic/University 
PI Contribution NA
Collaborator Contribution University of Leeds, Leeds, UK: Drs MA. Shaw, R. Quinnell, collaboration in studies on HLA associations with IgE responses and immunity in human schistosomiasis.
Impact NA
 
Description Drs. G. Kimani, JK. Mwatha (Kenyan Medical Research Institute) 
Organisation Kenyan Institute for Medical Research (KEMRI)
Country Kenya 
Sector Public 
PI Contribution NA
Collaborator Contribution provided field immunology, ultrasonography, and field laboratory support in both Kenya and Uganda
Impact NA
 
Description Professor A. Fenwick, Dr. NB. Kabatereine (National Schistosomiasis Control Programme) 
Organisation Imperial College London
Country United Kingdom 
Sector Academic/University 
PI Contribution NA
Collaborator Contribution Schistosomiasis Control Initiative, Imperial College, London, UK. Gates Foundation Uganda National Schistosomiasis Control Programme: Professor A. Fenwick, Dr. NB. Kabatereine, we provided training for Ugandan national control programme personnel in clinical and ultrasonography techniques for evaluating schistosomiasis morbidity and close cooperation between research project and control programme in Uganda ensured the success of complimentary research and control activities.
Impact NA
 
Description Professor JH. Ouma (University of Maseno, Kisumu, Kenya) 
Organisation Maseno University
Country Kenya 
Sector Academic/University 
PI Contribution NA
Collaborator Contribution provided field management support for vector and field studies in Kenya and Uganda
Impact NA
 
Description Professor Per Skov (The Danish National University Hospital) 
Organisation Rigshospitalet
Country Denmark 
Sector Hospitals 
PI Contribution NA
Collaborator Contribution The Danish National University Hospital, Copenhagen, Denmark: Professor Per Skov: collaboration in all aspects of studies on the interactions between IgE-mediated basophil function and human schistosomiasis.
Impact NA
 
Title Schistosomiasis hepatosplenic morbidity assessment 
Description Clinical and ultrasonographic examination methods that we devised to assess schistosomiasis hepatosplenic morbidity, in the present or absence of gross hepatic periportal fibrosis have be transferred to Ugandan National Schistosomiasis Control Programme staff and onwards to other sub-Saharan African countries that have initiated National Control Programmes with funding from the Bill and Melinda Gates 'Schistosomiasis Control Initiative, including Tanzania, Mali, Zambia. 
Type Diagnostic Tool - Imaging
Current Stage Of Development Small-scale adoption
Year Development Stage Completed 2006
Development Status Under active development/distribution
Impact Schistosomiasis mansoni is a serious public health problem in Uganda, with high transmission and severe morbidity. In addition to generating unique longitudinal data on the morbidity of, and immunity to, schistosomiasis, this programme provided data and training, which increased Ugandan operational capacity. The main Uganda parasitic disease control agency, the Ministry of Health's Vector Control Division (VCD), was moribund until 1994, when African Development Bank aid provided funds for its rehabilitation. Our collaborative studies with the Danish Bilharziasis Laboratory (DBL) and, in South-South collaboration, with the Ministry of Health of neighbouring Kenya, through it's Division of Vector Borne Diseases (DVBD) and Kenya Medical Research Institute (KEMRI) helped rebuild VCD's capacity in applied research and control. This was also facilitated by successive EC grants, which we coordinated between 1996 and 2004 that gave added value to MRC funding, and re-vitalization VCD to the point where it could be the first African partner in the Gates Foundation's Schistosomiasis Control Initiative (SCI) in sub-Saharan Africa, launched in Uganda March 2003. In the order of 3 million doses of PZQ have administered by SCI in the last 3 years, using the treatment regimen reported to be safe and effective in community-wide treatments in Piida and Booma. The clinical and ultrasonography methods being used to evaluate the efficacy of the control programme were devised and evaluated in our programme, and Kenyan and Ugandan colleagues have trained SCI staff in suitably modified methods for mass use. Our Ugandan and Kenyan staff have subsequently be involved in training technicians and nurses in other SCI target countries, including in Tanzania, Zambia, Mali and elsewhere. 
 
Description invited talks to KS2 and KS3 pupils at Lady Adrian School, Cambridge 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Primary Audience Schools
Results and Impact January 2006 invited talks to KS2 and KS3 pupils at Lady Adrian School, Cambridge, about the Matangini Project.

NA
Year(s) Of Engagement Activity 2006